1. Home
  2. CDNS vs VRTX Comparison

CDNS vs VRTX Comparison

Compare CDNS & VRTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Cadence Design Systems Inc.

CDNS

Cadence Design Systems Inc.

HOLD

Current Price

$330.41

Market Cap

106.8B

Sector

Technology

ML Signal

HOLD

Logo Vertex Pharmaceuticals Incorporated

VRTX

Vertex Pharmaceuticals Incorporated

HOLD

Current Price

$479.48

Market Cap

123.4B

Sector

Technology

ML Signal

HOLD

Company Overview

Basic Information
Metric
CDNS
VRTX
Founded
1988
1989
Country
United States
United States
Employees
N/A
N/A
Industry
Computer Software: Prepackaged Software
EDP Services
Sector
Technology
Technology
Exchange
Nasdaq
Nasdaq
Market Cap
106.8B
123.4B
IPO Year
1994
2006

Fundamental Metrics

Financial Performance
Metric
CDNS
VRTX
Price
$330.41
$479.48
Analyst Decision
Strong Buy
Buy
Analyst Count
14
29
Target Price
$375.00
$539.69
AVG Volume (30 Days)
2.0M
1.5M
Earning Date
04-27-2026
05-04-2026
Dividend Yield
N/A
N/A
EPS Growth
5.45
836.54
EPS
1.23
4.02
Revenue
$5,296,759,000.00
$2,488,652,000.00
Revenue This Year
$16.00
$10.79
Revenue Next Year
$12.39
$10.47
P/E Ratio
$268.67
$117.68
Revenue Growth
14.12
46.20
52 Week Low
$262.75
$362.50
52 Week High
$416.69
$533.67

Technical Indicators

Market Signals
Indicator
CDNS
VRTX
Relative Strength Index (RSI) 34.15 50.71
Support Level $331.56 $422.12
Resistance Level $341.31 $486.26
Average True Range (ATR) 13.52 14.20
MACD -4.80 -3.81
Stochastic Oscillator 16.96 21.95

Price Performance

Historical Comparison
CDNS
VRTX

About CDNS Cadence Design Systems Inc.

Cadence Design Systems is a provider of electronic design automation software, intellectual property, and system design and analysis products. EDA software automates and aids in the chip design process, enhancing design accuracy, productivity, and complexity in a full-flow end-to-end solution. Cadence offers a portfolio of design IP, as well as system design and analysis products, which enables system-level analysis and verification solutions.

About VRTX Vertex Pharmaceuticals Incorporated

Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio, and Alyftrek for cystic fibrosis, where Vertex therapies remain the standard of care globally. Vertex has diversified its portfolio through Casgevy, a gene-editing therapy for beta thalassemia and sickle-cell disease, and Journavx, a non-opioid pain medication approved for the treatment of moderate-to-severe acute pain in adults. Additionally, Vertex is evaluating small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.

Share on Social Networks: